Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
With a market cap of 136.92B, Vertex Pharmaceuticals(VRTX) trades at $554.01. The stock has a price-to-earnings ratio of 30.82.
On 2026-10-29, Vertex Pharmaceuticals(VRTX) stock traded between a low of $534.02 and a high of $554.01. Shares are currently priced at $554.01, which is +3.7% above the low and 0.0% below the high.
Vertex Pharmaceuticals(VRTX) shares are trading with a volume of 1.54M, against a daily average of 1.36M.
During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $403.16 at its lowest and $560.25 at its peak.
During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $403.16 at its lowest and $560.25 at its peak.
VRTX News
has delivered strong long term gains for shareholders, and the question now is whether the current US$529.69 share price is still aligned with the cash flows th...
Vertex Pharmaceuticals (VRTX Quick QuoteVRTX - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to...
We expect Vertex Pharmaceuticals (VRTX Quick QuoteVRTX - Free Report) to beat expectations when it reports third-quarter 2026 results on Nov. 2, after mar...
Analyst ratings
77%
of 35 ratingsMore VRTX News
Investing The $500 Million Non-CF Factor Vertex Investors Can’t Ignore on Nov. 2 Vertex Pharmaceuticals (NASDAQ:VRTX | VRTX Price Prediction) reports third-quar...
Vertex Pharmaceuticals reported Phase 3 RAINIER data for povetacicept in IgA nephropathy, with a 52.0% proteinuria reduction at Week 36 and a 49.8% decrease ver...
Vertex Pharmaceuticals (VRTX) just put its kidney program in the spotlight after reporting Phase 3 RAINIER data for povetacicept in IgA nephropathy, with strong...
Vertex Pharmaceuticals' (VRTX -2.10%) stable of cystic fibrosis (CF) therapies is one of the biggest monopolies among biotech companies. The company was founded...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.